News & Updates
Filter by Specialty:

Psychiatric comorbidity boosts healthcare use in youth with newly diagnosed SLE
Young patients with newly diagnosed systemic lupus erythematosus (SLE) are vulnerable to psychiatric comorbidity, which tends to increase healthcare utilization, according to a study.
Psychiatric comorbidity boosts healthcare use in youth with newly diagnosed SLE
09 Feb 2023
Biologic agents raise IBD risk among axSpA patients
Based on observational studies, patients with axial spondyloarthritis (axSpA) treated with biologics are at higher risk of inflammatory bowel disease (IBD), while findings from randomized controlled trials (RCTs) suggest that treatment with etanercept (ETN) tends to increase such risk compared to other antitumour necrosis factor (anti-TNF) therapies, according to the result of a meta-analysis.
Biologic agents raise IBD risk among axSpA patients
08 Feb 2023
Pharmacist-led collaborative gout clinic helps patients achieve serum uric acid goals
A collaborative clinic led by a pharmacist helps patients with gout to attain better clinical outcomes in the management of their condition, even in the presence of renal impairment, reports a Singapore study. The clinic provides safe, stepwise increments of urate-lowering therapy (ULT) in addition to serum uric acid (SUA) monitoring and adherence reinforcement through frequent initial visits.
Pharmacist-led collaborative gout clinic helps patients achieve serum uric acid goals
06 Feb 2023
Pain, discomfort persist in JIA patients despite medication use
Problems with pain or discomfort continue to bother young adults with juvenile idiopathic arthritis (JIA) despite their constant use of medication, a study has shown.
Pain, discomfort persist in JIA patients despite medication use
18 Jan 2023
Can RA patients taper MTX from targeted therapy?
A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.